January 23 , 2024 - Jiangsu Recbio Technology Co., Ltd.  ("Recbio" , HKEX:02179) is pleased to announce that the company has recently reached a License and strategic cooperation with the Saudi Arabian pharmaceutical company SPIMACO for the recombinant HPV-9 vaccine REC603. According to the agreement, Recbio exclusively authorizes SPIMACO to develop, register and commercialize the HPV-9 vaccine REC603 in 15 Middle East and North African countries, including Saudi Arabia.

This strategic cooperation covers a total population of approximately 380 million in the Middle East and North African countries. Cervical cancer is the eighth most common cancer in Saudi Arabia and the eighth most common chronic cancer among women aged 15-44. The nine-valent HPV vaccine is widely regarded as the most effective vaccine against HPV and can prevent about 90% of cervical cancer and 90% of anal and genital warts. SPIMACO is one of the largest listed pharmaceutical companies in Saudi Arabia. The company is deeply involved in the government-funded and private self-pay markets in the Middle East and North Africa, and its products widely cover the Middle East and North Africa countries. The cooperation between the Company and SPIMACO will help the Company explore the Middle East, North Africa and other markets and accelerate the commercialization process of innovative vaccines.

The company's core product, the recombinant nine-valent HPV vaccine REC603, is suitable for people aged 9 to 45 years old. It has shown good safety and immunogenicity in previous studies and is currently in the Phase III clinical stage in China. REC603 uses Hansenula yeast expression system, which can achieve high production and stable expression of HPV virus-like particles, making the company's vaccine candidate more suitable for commercial production. The company's HPV vaccine manufacturing facility is constructed in accordance with the requirements of the WHO pre-qualification(WHO PQ)  system and can meet the annual production capacity of up to 20 million doses of recombinant HPV-9 vaccine.

Dr. Liu Yong, founder of Recbio, stated:We are thrilled to forge this alliance with SPIMACO, a true champion in the region. This collaboration represents a powerful synergy between our expertise and SPIMACO's established presence in the Middle East and North Africa. With Recbio's 9-valent HPV vaccine nearing commercialization, this is the perfect moment to join forces and ensure its swift and efficient market entry across 15 countries, benefiting populations throughout the MENA region.” 

Jerome Cabannes, CEO of SPIMACO, added: “This collaboration with Recbio strengthens SPIMACO’s dedication to advancing Health Transformation in Saudi Arabia, marking a significant milestone in the Kingdom's pursuit of becoming a pivotal hub for pharmaceutical manufacturing. SPIMACO remains committed to delivering innovative, high-quality, and affordable vaccines, aiming to enhance preventive care and overall population health in the region."

About SPIMACO

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO, Tadawul: 2070), headquartered in Riyadh, Saudi Arabia, is a leading pharmaceutical manufacturer extending its operations to 16 countries. Renowned for its production of high-quality generics, SPIMACO serves a diverse range of over 60 therapeutic categories, establishing itself as a strategic partner for major global and regional pharmaceutical companies.

Operating out of two state-of-the-art production facilities in Qassim and Dammam, the company boasts 7 production lines with a combined capacity exceeding 1,750 million units annually, and offers a wide range of pharmaceutical products including Oral Solids & Liquids, Creams, Aseptic Injectables, Suppositories, and Active Pharmaceutical Ingredients (APIs). With a dedicated workforce of over 1,200 employees, SPIMACO is steadfast in its commitment to sustainable growth and innovation.

About Recbio

Founded in 2012, Jiangsu Recbio Technology Co., Ltd (Recbio, HKEK:2179) is an innovative vaccine company driven by self-developed technologies. The Company is dedicated to the R&D, production, and commercialization of innovative vaccines, leveraging its core technology platforms (novel adjuvant, protein engineering, immunological evaluation). Staying true to the mission of “Protect human health with best-in-class vaccines”, Recbio has established high-value pipelines consisting of several blockbuster vaccines with proprietary rights to satisfy the huge unmet demands in the markets of high-burden diseases. With robust R&D capacity, the Company has developed high-value innovative vaccine portfolios covering cervical cancer, shingles, COVID-19, Respiratory Syncytial Virus (RSV), Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), tuberculosis (TB) and other high-burden diseases.

Forward-looking statements

This Press Release may contain projections, estimates, forecasts, targets, opinions, prospects, results, returns and forward-looking statements with respect to the financial condition, results of operations, capital position, strategy and business of the Group which can be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “anticipate”, “project”, “plan”, “estimate”, “seek”, “intend”, “target”, “believe”, “potential” and “reasonably possible” or the negatives thereof or other variations thereon or comparable terminology (collectively, “forward-looking statements”), including the strategic priorities, research and development projects, and any financial, investment and capital targets and any other targets, commitments and ambitions described in writing or verbally herein. Any such forward-looking statements are not a reliable indicator of future performance, as they may involve significant stated or implied assumptions and subjective judgements which may or may not prove to be correct, accurate or complete. There can be no assurance that any of the matters set out in the forward-looking statements are attainable, will actually occur or will be realised or are complete or accurate. The assumptions and judgments may prove to be incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other important actors, many of which are outside the control of the Group. There is also no assurance that the Group may develop or market its core products or other pipeline candidates successfully. Actual achievements, results, performance or other future events or conditions may differ materially from those stated, implied and/or reflected in any forward-looking statements due to a variety of risks, uncertainties and other factors (including without limitation general market conditions, regulatory changes, geopolitical tensions or data limitations and changes). Any such forward-looking statements are based on the beliefs, expectations and opinions of the Group at the date the statements are made, and the Group does not assume, and hereby disclaims, any obligation or duty to update, revise or supplement them if circumstances or management’s beliefs, expectations or opinions should change. For these reasons, you should not place reliance on, and are expressly cautioned about relying on, any forward-looking statements. No representations or warranties, expressed or implied, are given by  or on behalf of the Group as to the achievement or reasonableness of any projections, estimates, forecasts, targets, commitments, prospects or returns contained herein.

Please refer to the announcements published by the Company on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnew.hk) or of the Company (qkg.jiajufangshui.com) for further details. If there is any inconsistency between this Presentation and the announcements, the announcements shall prevail.

Jiangsu Recbio Technology Co., Ltd.

Investor Inquiry:

Email: ir@jiajufangshui.com

Tel: +86-0523-86818860

Media Inquiry:

Email: media@jiajufangshui.com

Tel: +86-0523-86818860

Related Links:

http://qkg.jiajufangshui.com/en/

SOURCE ：Jiangsu Recbio Technology Co., Ltd.